Overview

Location [1]
12q13.12
Protein [2]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1
Synonyms [1]
CSS11, BAF60A, Rsc6p, CRACD1

SMARCD1 is altered in 0.66% of all cancers with colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].

SMARCD1 GENIE Cases - Top Diseases

The most common alterations in SMARCD1 are SMARCD1 Amplification (0.09%), SMARCD1 Loss (0.06%), SMARCD1 R183Q (0.02%), SMARCD1 A115V (0.01%), and SMARCD1 P12S (0.01%) [3].

SMARCD1 GENIE Cases - Top Alterations

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.